Most-cited articles · 2023

The 50 most-cited articles in Radiotherapy and Oncology, 2023

Ranked by OpenAlex citation count on 29 October 2026, out of 776 eligible articles Radiotherapy and Oncology published in 2023. Ranks are frozen; this page will not change. Number one, with 236 citations: ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma.

Cohort
776 articles
Listed
Top 50 (6.4%)
Open access
35 of 50
Snapshot
2026-10-29

The most-cited articles from Radiotherapy and Oncology in 2023 are led by clinical practice guidelines, particularly from ESTRO and its partner societies. The top paper is the ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma, with 236 citations. Other highly cited guidelines address breath-hold techniques, stereotactic body radiotherapy for spine metastases, and cervical cancer management. Alongside guidelines, the list features prospective studies on adaptive radiotherapy, including stereotactic MR-guided on-table adaptive radiation therapy for pancreatic cancer and same-day palliative treatment, as well as research on FLASH radiotherapy and re-irradiation.

Readers can use this list to identify the topics and document types that attracted the most citations in the journal in 2023. It reflects a mix of consensus recommendations, prospective clinical trials, systematic reviews, and technical developments. The ranking is based on OpenAlex citation counts and covers 776 eligible articles.

Introduction written from the titles and abstracts on this list. Every figure below is the source.

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.2%

    ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma

    Maximilian Niyazi, Nicolaus H. Andratschke, Martin Bendszus, Anthony J. Chalmers, Sara Erridge and 9 more

    236 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109663OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Target delineation in glioblastoma is still a matter of extensive research and debate. This guideline aims to update the existing joint European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients. MATERIAL AND METHODS: The ESTRO Guidelines Committee identified 14 European experts in close interaction with the ESTRO clinical committee and EANO who discussed and analysed the body of evidence concerning contemporary glioblastoma target delineation, then took part in a two-step modified Delphi process to address open questions. RESULTS: Several key issues were identified and are discussed including i) pre-treatment steps and immobilisation, ii) target delineation and the use of standard and novel imaging techniques, and iii) technical aspects of treatment including planning techniques and fractionation. Based on the EORTC recommendation focusing on the resection cavity and residual enhancing regions on T1-sequences with the addition of a reduced 15 mm margin, special situations are presented with corresponding potential…

  2. 2
    top 0.3%

    Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study

    Michael David Chuong, Percy P. Lee, Daniel A. Low, Joshua P. Kim, Kathryn Elizabeth Mittauer and 25 more

    124 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.110064OpenAlex

    Show abstract

    Background and purpose Radiation dose escalation may improve local control (LC) and overall survival (OS) in select pancreatic ductal adenocarcinoma (PDAC) patients. We prospectively evaluated the safety and efficacy of ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC). The primary endpoint of acute grade ≥ 3 gastrointestinal (GI) toxicity definitely related to SMART was previously published with median follow-up (FU) 8.8 months from SMART. We now present more mature outcomes including OS and late toxicity. Materials and methods This prospective, multi-center, single-arm open-label phase 2 trial (NCT03621644) enrolled 136 patients (LAPC 56.6%; BRPC 43.4%) after ≥ 3 months of any chemotherapy without distant progression and CA19-9 ≤500 U/mL. SMART was delivered on a 0.35T MR-guided system prescribed to 50 Gy in 5 fractions (biologically effective dose 10 [BED 10 ]=100 Gy). Elective coverage was optional. Surgery and chemotherapy were permitted after SMART. Results Mean…

  3. 3
    top 0.4%

    ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy

    Marianne Camille Aznar, Pablo Carrasco, Stefanie Corradini, Mirjam E. Mast, Helen A. McNair and 3 more

    124 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109734OpenAlex

    Show abstract

    The use of breath-hold techniques in radiotherapy, such as deep-inspiration breath hold, is increasing although guidelines for clinical implementation are lacking. In these recommendations, we aim to provide an overview of available technical solutions and guidance for best practice in the implementation phase. We will discuss specific challenges in different tumour sites including factors such as staff training and patient coaching, accuracy, and reproducibility. In addition, we aim to highlight the need for further research in specific patient groups. This report also reviews considerations for equipment, staff training and patient coaching, as well as image guidance for breath-hold treatments. Dedicated sections for specific indications, namely breast cancer, thoracic and abdominal tumours are also included.

  4. 4
    top 0.6%

    Applicability and usage of dose mapping/accumulation in radiotherapy

    Martina Murr, Kristy K. Brock, Marco Fusella, Nicholas Hardcastle, Mohammad Hussein and 5 more

    96 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109527OpenAlex

    Show abstract

    Dose mapping/accumulation (DMA) is a topic in radiotherapy (RT) for years, but has not yet found its widespread way into clinical RT routine. During the ESTRO Physics workshop 2021 on "commissioning and quality assurance of deformable image registration (DIR) for current and future RT applications", we built a working group on DMA from which we present the results of our discussions in this article. Our aim in this manuscript is to shed light on the current situation of DMA in RT and to highlight the issues that hinder consciously integrating it into clinical RT routine. As a first outcome of our discussions, we present a scheme where representative RT use cases are positioned, considering expected anatomical variations and the impact of dose mapping uncertainties on patient safety, which we have named the DMA landscape (DMAL). This tool is useful for future reference when DMA applications get closer to clinical day-to-day use. Secondly, we discussed current challenges, lightly touching on first-order effects (related to the impact of DIR uncertainties in dose mapping), and focusing…

  5. 5
    top 0.7%

    ESTRO clinical practice guideline: Stereotactic body radiotherapy for spine metastases

    Matthias Gückenberger, Nicolaus H. Andratschke, Claus Belka, David Bellut, Francesco Cuccia and 12 more

    87 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109966OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Recent progress in diagnostics and treatment of metastatic cancer patients have improved survival substantially. These developments also affect local therapies, with treatment aims shifting from short-term palliation to long-term symptom or disease control. There is consequently a need to better define the value of stereotactic body radiotherapy (SBRT) for the treatment of spinal metastases. METHODS: This ESTRO clinical practice guideline is based on a systematic literature review conducted according to PRISMA standards, which formed the basis for answering four key questions about the indication and practice of SBRT for spine metastases. RESULTS: The analysis of the key questions based on current evidence yielded 22 recommendations and 5 statements with varying levels of endorsement, all achieving a consensus among experts of at least 75%. In the majority, the level of evidence supporting the recommendations and statements was moderate or expert opinion, only, indicating that spine SBRT is still an evolving field of clinical research. Recommendations were…

  6. 6
    top 0.8%

    Same-day adaptive palliative radiotherapy without prior CT simulation: Early outcomes in the FAST-METS study

    Koen J. Nelissen, Eva Versteijne, Suresh Senan, Barbara L.T. Rijksen, Marjan A. Admiraal and 6 more

    85 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109538OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Standard palliative radiotherapy workflows involve waiting times or multiple clinic visits. We developed and implemented a rapid palliative workflow using diagnostic imaging (dCT) for pre-planning, with subsequent on-couch target and plan adaptation based on a synthetic computed tomography (CT) obtained from cone-beam CT imaging (CBCT). MATERIALS AND METHODS: Patients with painful bone metastases and recent diagnostic imaging were eligible for inclusion in this prospective, ethics-approved study. The workflow consisted of 1) telephone consultation with a radiation oncologist (RO); 2) pre-planning on the dCT using planning templates and mostly intensity-modulated radiotherapy; 3) RO consultation on the day of treatment; 4) CBCT scan with on-couch adaptation of the target and treatment plan; 5) delivery of either scheduled or adapted treatment plan. Primary outcomes were dosimetric data and treatment times; secondary outcome was patient satisfaction. RESULTS: 47 patients were enrolled between December 2021 and October 2022. In all treatments, adapted treatment…

  7. 7
    top 1%

    Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform

    Jonas Willmann, Ane Lindegaard Appelt, Panagiotis Balermpas, Brigitta G. Baumert, Dirk De Ruysscher and 11 more

    84 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109947OpenAlex

    Show abstract

    BACKGROUND: Re-irradiation is an increasingly utilized treatment for recurrent, metastatic or new malignancies after previous radiotherapy. It is unclear how re-irradiation is applied in clinical practice. We aimed to investigate the patterns of care of re-irradiation internationally. MATERIAL/METHODS: A cross-sectional survey conducted between March and September 2022. The survey was structured into six sections, each corresponding to a specific anatomical region. Participants were instructed to complete the sections of their clinical expertise. A total of 15 multiple-choice questions were included in each section, addressing various aspects of the re-irradiation process. The online survey targeted radiation and clinical oncologists and was endorsed by the European Society for Radiotherapy and Oncology (ESTRO) and the European Organisation for Research and Treatment of Cancer (EORTC). RESULTS: 371 physicians from 55 countries across six continents participated. Participants had a median professional experience of 16 years, and the majority (60%) were affiliated with an academic…

  8. 8
    top 1.1%

    Ultra-high dose-rate proton FLASH improves tumor control

    Samriddhi Shukla, Taniya Saha, Nihar Rama, Anusha Acharya, Tien T. Le and 8 more

    78 citationsOpen accessdoi:10.1016/j.radonc.2023.109741OpenAlex

  9. 9
    top 1.2%

    Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline

    Ricarda Stella Guninski, Francesco Cuccia, Filippo Alongi, Nicolaus H. Andratschke, Claus Belka and 13 more

    76 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109969OpenAlex

    Show abstract

    Background and purpose Advances in characterizing cancer biology and the growing availability of novel targeted agents and immune therapeutics have significantly changed the prognosis of many patients with metastatic disease. Palliative radiotherapy needs to adapt to these developments. In this study, we summarize the available evidence for stereotactic body radiotherapy (SBRT) in the treatment of spinal metastases. Materials and methods A systematic review and meta-analysis was performed using PRISMA methodology, including publications from January 2005 to September 2021, with the exception of the randomized phase III trial RTOG-0631 which was added in April 2023. Re-irradiation was excluded. For meta-analysis, a random-effects model was used to pool the data. Heterogeneity was assessed with the I 2 -test, assuming substantial and considerable as I 2 >50% and I 2 >75%, respectively. A p-value <0.05 was considered statistically significant. Results A total of 69 studies assessing the outcomes of 7236 metastases in 5736 patients were analyzed. SBRT for spine metastases showed high…

  10. 10
    top 1.3%

    ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

    David Cibula, Maria Rosaria Raspollini, François Planchamp, Carlos Centeno, Cyrus Chargari and 22 more

    76 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109682OpenAlex

    Show abstract

    In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with cervical cancer. Given the large body of new evidence addressing the management of cervical cancer, the three sister societies jointly decided to update these evidence-based guidelines. The update includes new topics to provide comprehensive guidelines on all relevant issues of diagnosis and treatment in cervical cancer. To serve on the expert panel (27 experts across Europe) ESGO/ESTRO/ESP nominated practicing clinicians who are involved in managing patients with cervical cancer and have demonstrated leadership through their expertise in clinical care and research, national and international engagement, profile, and dedication to the topics addressed. To ensure the statements were evidence based, new data identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment…

  11. 11
    top 1.5%

    The sparing effect of FLASH-RT on synaptic plasticity is maintained in mice with standard fractionation

    Charles L. Limoli, Enikö A. Kramár, Aymeric Almeida, Benoît Petit, Veljko Grilj and 5 more

    70 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109767OpenAlex

    Show abstract

    Long-term potentiation (LTP) was used to gauge the impact of conventional and FLASH dose rates on synaptic transmission. Data collected from the hippocampus and medial prefrontal cortex confirmed significant inhibition of LTP after 10 fractions of 3 Gy (30 Gy total) conventional radiotherapy. Remarkably, 10x3Gy FLASH radiotherapy and unirradiated controls were identical and exhibited normal LTP.

  12. 12
    top 1.6%

    EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study

    Ping Peng, Juejun Gong, Yujie Zhang, Shuchang Zhou, Yichen Li and 11 more

    69 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109681OpenAlex

    Show abstract

    BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, the acquired resistance greatly limits the survival benefit of EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus EGFR-TKIs in these patients. METHODS: In this prospective, randomized, controlled, phase 2 study, participants were recruited from 4 different hospitals in Wuhan, China. Eligible patients were histologically confirmed to have NSCLC with an EGFR-sensitive mutation (19DEL or 21L858R) and diagnosed at stage IV. Patients who had received first-line EGFR-TKIs treatment including gefitinib, erlotinib, and icotinib and achieved stable disease or partial response were enrolled after three months. Eligible participants were randomly assigned (1:1) to receive SBRT plus EGFR-TKIs or EGFR-TKIs treatment alone. In the combination-group, different tumor sites were irradiated at doses ranging…

  13. 13
    top 1.7%

    Consensus guide on CT-based prediction of stopping-power ratio using a Hounsfield look-up table for proton therapy

    Nils Peters, Vicki Trier Taasti, Benjamin Ackermann, Alessandra Bolsi, Christina Vallhagen Dahlgren and 13 more

    69 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109675OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Studies have shown large variations in stopping-power ratio (SPR) prediction from computed tomography (CT) across European proton centres. To standardise this process, a step-by-step guide on specifying a Hounsfield look-up table (HLUT) is presented here. MATERIALS AND METHODS: The HLUT specification process is divided into six steps: Phantom setup, CT acquisition, CT number extraction, SPR determination, HLUT specification, and HLUT validation. Appropriate CT phantoms have a head- and body-sized part, with tissue-equivalent inserts in regard to X-ray and proton interactions. CT numbers are extracted from a region-of-interest covering the inner 70% of each insert in-plane and several axial CT slices in scan direction. For optimal HLUT specification, the SPR of phantom inserts is measured in a proton beam and the SPR of tabulated human tissues is computed stoichiometrically at 100 MeV. Including both phantom inserts and tabulated human tissues increases HLUT stability. Piecewise linear regressions are performed between CT numbers and SPRs for four tissue…

  14. 14
    top 1.9%

    Gating and intrafraction drift correction on a 1.5 T MR-Linac: Clinical dosimetric benefits for upper abdominal tumors

    Guus Grimbergen, Sara Lyons Hackett, Fasco van Ommen, Astrid L.H.M.W. van Lier, Pim Borman and 6 more

    63 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109932OpenAlex

    Show abstract

    This work reports on the first seven patients treated with gating and baseline drift correction on the high-field MR-Linac system. Dosimetric analysis showed that the active motion management system improved congruence to the planned dose, efficiently mitigating detrimental effects of intrafraction motion in the upper abdomen.

  15. 15
    top 2%

    Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis

    Viola Salvestrini, Kyubo Kim, Saverio Caini, Sara Alkner, Maria Ekholm and 17 more

    60 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109805OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: In recent years, the treatment landscape for breast cancer has undergone significant advancements, with the introduction of several new anticancer agents. One such agent is trastuzumab emtansine (T-DM1), an antibody drug conjugate that has shown improved outcomes in both early and advanced breast cancer. However, there is currently a lack of comprehensive evidence regarding the safety profile of combining T-DM1 with radiation therapy (RT). In this study, we aim to provide a summary of the available data on the safety of combining RT with T-DM1 in both early and metastatic breast cancer settings. MATERIALS AND METHODS: This systematic review and meta-analysis project is part of the consensus recommendations by the European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee on integrating RT with targeted treatments for breast cancer. A thorough literature search was conducted using the PUBMED/MedLine, Embase, and Cochrane databases to identify original studies focusing on the safety profile of combining T-DM1 with RT. RESULTS: After applying…

  16. 16
    top 2.1%
  17. 18
    top 2.4%

    Real-time motion management in MRI-guided radiotherapy: Current status and AI-enabled prospects

    Elia Lombardo, Jennifer Dhont, Denis Page, Cristina Garibaldi, Luise A. Künzel and 11 more

    52 citationsdoi:10.1016/j.radonc.2023.109970OpenAlex

  18. 19
    top 2.5%

    Treatment plan optimisation for reirradiation

    Louise Janet Murray, Christopher M. Thompson, Christopher Pagett, J. Lilley, Bashar M. Al‐Qaisieh and 7 more

    49 citationsdoi:10.1016/j.radonc.2023.109545OpenAlex

  19. 20
    top 2.6%

    Stereotactic Arrhythmia Radioablation (STAR): Assessment of cardiac and respiratory heart motion in ventricular tachycardia patients - A STOPSTORM.eu consortium review

    Raoul R. F. Stevens, Colien Hazelaar, Martin F. Fast, Stefano Mandija, Melanie Grehn and 7 more

    48 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109844OpenAlex

    Show abstract

    AIM: To identify the optimal STereotactic Arrhythmia Radioablation (STAR) strategy for individual patients, cardiorespiratory motion of the target volume in combination with different treatment methodologies needs to be evaluated. However, an authoritative overview of the amount of cardiorespiratory motion in ventricular tachycardia (VT) patients is missing. METHODS: In this STOPSTORM consortium study, we performed a literature review to gain insight into cardiorespiratory motion of target volumes for STAR. Motion data and target volumes were extracted and summarized. RESULTS: Out of the 232 studies screened, 56 provided data on cardiorespiratory motion, of which 8 provided motion amplitudes in VT patients (n = 94) and 10 described (cardiac/cardiorespiratory) internal target volumes (ITVs) obtained in VT patients (n = 59). Average cardiac motion of target volumes was < 5 mm in all directions, with maximum values of 8.0, 5.2 and 6.5 mm in Superior-Inferior (SI), Left-Right (LR), Anterior-Posterior (AP) direction, respectively. Cardiorespiratory motion of cardiac (sub)structures…

  20. 21
    top 2.8%

    Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A nonrandomized controlled trial

    Raphael Bodensohn, Anna-Lena Kaempfel, Anne‐Laure Boulesteix, Anna Maria Orzelek, Stefanie Corradini and 11 more

    48 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109744OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: There is no randomized evidence comparing whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in the treatment of multiple brain metastases. This prospective nonrandomized controlled single arm trial attempts to reduce the gap until prospective randomized controlled trial results are available. MATERIAL AND METHODS: We included patients with 4-10 brain metastases and ECOG performance status ≤ 2 from all histologies except small-cell lung cancer, germ cell tumors, and lymphoma. The retrospective WBRT-cohort was selected 2:1 from consecutive patients treated within 2012-2017. Propensity-score matching was performed to adjust for confounding factors such as sex, age, primary tumor histology, dsGPA score, and systemic therapy. SRS was performed using a LINAC-based single-isocenter technique employing prescription doses from 15-20Gyx1 at the 80% isodose line. The historical control consisted of equivalent WBRT dose regimens of either 3Gyx10 or 2.5Gyx14. RESULTS: Patients were recruited from 2017-2020, end of follow-up was July 1st, 2021. 40…

  21. 22
    top 2.9%

    Brain metastasis tumor segmentation and detection using deep learning algorithms: A systematic review and meta-analysis

    Tingwei Wang, Ming‐Sheng Hsu, Wei‐Kai Lee, Hung-Chuan Pan, Huai‐Che Yang and 2 more

    46 citationsdoi:10.1016/j.radonc.2023.110007OpenAlex

  22. 23
    top 3%

    Computed tomography and radiation dose images-based deep-learning model for predicting radiation pneumonitis in lung cancer patients after radiation therapy

    Zhen Zhang, Zhixiang Wang, Tianchen Luo, Meng Yan, Andre L.A.J. Dekker and 4 more

    46 citationsOpen access (OTHER-OA)doi:10.1016/j.radonc.2023.109581OpenAlex

    Show abstract

    PURPOSE: To develop a deep learning model that combines CT and radiation dose (RD) images to predict the occurrence of radiation pneumonitis (RP) in lung cancer patients who received radical (chemo)radiotherapy. METHODS: CT, RD images and clinical parameters were obtained from 314 retrospectively-collected patients (training set) and 35 prospectively-collected patients (test-set-1) who were diagnosed with lung cancer and received radical radiotherapy in the dose range of 50 Gy and 70 Gy. Another 194 (60 Gy group, test-set-2) and 158 (74 Gy group, test-set-3) patients from the clinical trial RTOG 0617 were used for external validation. A ResNet architecture was used to develop a prediction model that combines CT and RD features. Thereafter, the CT and RD weights were adjusted by using 40 patients from test-set-2 or 3 to accommodate cohorts with different clinical settings or dose delivery patterns. Visual interpretation was implemented using a gradient-weighted class activation map (grad-CAM) to observe the area of model attention during the prediction process. To improve the…

  23. 24
    top 3.1%

    Modeling frameworks for radiation induced lymphopenia: A critical review

    Laura Cella, Serena Monti, Roberto Pacelli, Giuseppe Palma

    45 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.110041OpenAlex

    Show abstract

    Radiation-induced lymphopenia (RIL) is a frequent, and often considered unavoidable, side effect of radiation therapy (RT), whether or not chemotherapy is included. However, in the last few years several studies have demonstrated the detrimental effect of RIL on therapeutic outcomes, with conflicting findings concerning possible inferior patient survival. In addition, since immunotherapeutic treatment has become an integral part of cancer therapy, preserving the immune system is recognized as crucial. Given this background, various research groups have reported on different frameworks for modelling RIL, frequently based on different definitions of RIL itself, and discordant results have been reported. Our aim is to critically review the current literature on RIL modelling and summarize the different approaches recently proposed to improve the prediction of RIL after RT and aimed at immunity-sparing RT. A detailed description of these approaches will be outlined and illustrated through their applications as found in the literature from the last five years. Such a critical analysis…

  24. 27
    top 3.5%

    Survival prediction for stage I-IIIA non-small cell lung cancer using deep learning

    Sunyi Zheng, Jiapan Guo, Johannes Albertus Langendijk, Stefan Both, Raymond N. J. Veldhuis and 4 more

    44 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109483OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: The aim of this study was to develop and evaluate a prediction model for 2-year overall survival (OS) in stage I-IIIA non-small cell lung cancer (NSCLC) patients who received definitive radiotherapy by considering clinical variables and image features from pre-treatment CT-scans. MATERIALS AND METHODS: NSCLC patients who received stereotactic radiotherapy were prospectively collected at the UMCG and split into a training and a hold out test set including 189 and 81 patients, respectively. External validation was performed on 228 NSCLC patients who were treated with radiation or concurrent chemoradiation at the Maastro clinic (Lung1 dataset). A hybrid model that integrated both image and clinical features was implemented using deep learning. Image features were learned from cubic patches containing lung tumours extracted from pre-treatment CT scans. Relevant clinical variables were selected by univariable and multivariable analyses. RESULTS: Multivariable analysis showed that age and clinical stage were significant prognostic clinical factors for 2-year OS.…

  25. 28
    top 3.7%

    The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC

    Cole Friedes, Michelle Iocolano, Sang Ho Lee, Lian Duan, Bolin Li and 13 more

    43 citationsdoi:10.1016/j.radonc.2023.110030OpenAlex

  26. 29
    top 3.8%

    Challenges of re-irradiation: A call to arms for physicists - and radiotherapy vendors

    Eliana Maria Vasquez Osorio, Charles Mayo, Andrew Jackson, Ane Lindegaard Appelt

    43 citationsdoi:10.1016/j.radonc.2023.109585OpenAlex

  27. 30
    top 3.9%

    Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic

    Bas A. de Jong, Erik W. Korevaar, Anneke Maring, Chimène I. Werkman, Daniel Scandurra and 3 more

    41 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109670OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: In the model-based approach, patients qualify for proton therapy when the reduction in risk of toxicity (ΔNTCP) obtained with IMPT relative to VMAT is larger than predefined thresholds as defined by the Dutch National Indication Protocol (NIPP). Proton arc therapy (PAT) is an emerging technology which has the potential to further decrease NTCPs compared to IMPT. The aim of this study was to investigate the potential impact of PAT on the number of oropharyngeal cancer (OPC) patients that qualify for proton therapy. MATERIALS AND METHODS: A prospective cohort of 223 OPC patients subjected to the model-based selection procedure was investigated. 33 (15%) patients were considered unsuitable for proton treatment before plan comparison. When IMPT was compared to VMAT for the remaining 190 patients, 148 (66%) patients qualified for protons and 42 (19%) patients did not. For these 42 patients treated with VMAT, robust PAT plans were generated. RESULTS: PAT plans provided better or similar target coverage compared to IMPT plans. In the PAT plans, integral dose was…

  28. 31
    top 4%

    Dosimetric and biologic intercomparison between electron and proton FLASH beams

    Aymeric Almeida, Michele Togno, Paola Ballesteros‐Zebadúa, Javier Franco‐Pérez, R. Geyer and 10 more

    40 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109953OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: The FLASH effect has been validated in different preclinical experiments with electrons (eFLASH) and protons (pFLASH) operating at an average dose rate above 40 Gy/s. However, no systematic intercomparison of the FLASH effect produced by eFLASHvs. pFLASH has yet been performed and constitutes the aim of the present study. MATERIALS AND METHODS: The electron eRT6/Oriatron/CHUV/5.5 MeV and proton Gantry1/PSI/170 MeV were used to deliver conventional (0.1 Gy/s eCONV and pCONV) and FLASH (≥110 Gy/s eFLASH and pFLASH) dose rates. Protons were delivered in transmission. Dosimetric and biologic intercomparisons were performed using previously validated dosimetric approaches and experimental murine models. RESULTS: The difference between the average absorbed dose measured at Gantry 1 with PSI reference dosimeters and with CHUV/IRA dosimeters was -1.9 % (0.1 Gy/s) and + 2.5 % (110 Gy/s). The neurocognitive capacity of eFLASH and pFLASH irradiated mice was indistinguishable from the control, while both eCONV and pCONV irradiated cohorts showed cognitive decrements.…

  29. 33
    top 4.3%
  30. 35
    top 4.6%

    Radiation dose to heart and cardiac substructures and risk of coronary artery disease in early breast cancer patients: A DBCG study based on modern radiation therapy techniques

    Marie Louise Holm Milo, Ditte Sloth Møller, Tine Bisballe Nyeng, Lone Hoffmann, Henrik Dahl Nissen and 8 more

    39 citationsdoi:10.1016/j.radonc.2022.109453OpenAlex

  31. 36
    top 4.7%

    Prospective evaluation of in vivo and phantom repeatability and reproducibility of diffusion-weighted MRI sequences on 1.5 T MRI-linear accelerator (MR-Linac) and MR simulator devices for head and neck cancers

    Brigid A. McDonald, Travis C. Salzillo, Samuel L. Mulder, Sara Ahmed, Alex Dresner and 11 more

    38 citationsOpen access (CC-BY-NC)doi:10.1016/j.radonc.2023.109717OpenAlex

    Show abstract

    Introduction Diffusion-weighted imaging (DWI) on MRI-linear accelerator (MR-linac) systems can potentially be used for monitoring treatment response and adaptive radiotherapy in head and neck cancers (HNC) but requires extensive validation. We performed technical validation to compare six total DWI sequences on an MR-linac and MR simulator (MR sim) in patients, volunteers, and phantoms. Methods Ten human papillomavirus-positive oropharyngeal cancer patients and ten healthy volunteers underwent DWI on a 1.5T MR-linac with three DWI sequences: echo planar imaging (EPI), split acquisition of fast spin echo signals (SPLICE), and turbo spin echo (TSE). Volunteers were also imaged on a 1.5T MR sim with three sequences: EPI, BLADE (vendor tradename), and readout segmentation of long variable echo trains (RESOLVE). Participants underwent two scan sessions per device and two repeats of each sequence per session. Repeatability and reproducibility within-subject coefficient of variation (wCV) of mean ADC were calculated for tumors and lymph nodes (patients) and parotid glands (volunteers). ADC…

  32. 37
    top 4.8%

    Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Orit Kaidar‐Person, Icro Meattini, Liesbeth Jorinne Boersma, Carlotta Becherini, Javier Cortés and 20 more

    37 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.110060OpenAlex

    Show abstract

    The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in RT (QART) plays a pivotal role in influencing treatment outcomes. Clinical trials incorporating QART protocols have demonstrated improved survival rates with minimal associated toxicity. Nonetheless, in routine clinical practice, there can be variability in the indications for RT, dosage, fractionation, and treatment planning, leading to uncertainty. In pivotal trials reporting outcomes of systemic therapy for breast cancer, there is limited information available regarding RT, and the potential interaction between modern systemic therapy and RT remains largely uncharted. This article is grounded in a consensus recommendation endorsed by ESTRO, formulated by international breast cancer experts. The consensus was reached through a modified Delphi process and was presented at an international meeting convened in Florence, Italy, in June 2023. These…

  33. 38
    top 4.9%

    Deep learning–based automatic segmentation of cardiac substructures for lung cancers

    Xinru Chen, Raymond P. Mumme, Kelsey L. Corrigan, Yuki Mukai-Sasaki, Efstratios Koutroumpakis and 15 more

    37 citationsOpen accessdoi:10.1016/j.radonc.2023.110061OpenAlex

  34. 40
    top 5.2%

    Enabling ultra-high dose rate electron beams at a clinical linear accelerator for isocentric treatments

    Riccardo Dal Bello, Jens von der Grün, Silvia Fabiano, Thomas Rudolf, Natalia Saltybaeva and 7 more

    36 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109822OpenAlex

    Show abstract

    Background and Purpose Radiotherapy delivery with ultra-high dose rates (UHDR) has consistently produced normal tissue sparing while maintaining efficacy for tumour control in preclinical studies, known as the FLASH effect. Modified clinical electron linacs have been used for pre-clinical studies at reduced source-surface distance (SSD) and novel intra-operative devices are becoming available. In this context, we modified a clinical linac to deliver 16 MeV UHDR electron beams with an isocentric setup. Materials and Methods The first Varian TrueBeam (SN 1001) was clinically operative between 2009–2022, it was then decommissioned and converted into a research platform. The 18 MeV electron beam was converted into the experimental 16 MeV UHDR. Modifications were performed by Varian and included a software patch, thinner scattering foil and beam tuning. The dose rate, beam characteristics and reproducibility were measured with electron applicators at SSD=100 cm. Results The dose per pulse at isocenter was up to 1.28 Gy/pulse, corresponding to average and instantaneous dose rates up to…

  35. 41
    top 5.3%

    Benefits of automated gross tumor volume segmentation in head and neck cancer using multi-modality information

    Heleen Bollen, Siri Willems, M. Wegge, Frederik Maes, Sandra Nuyts

    35 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109574OpenAlex

    Show abstract

    Purpose Gross tumor volume (GTV) delineation for head and neck cancer (HNC) radiation therapy planning is time consuming and prone to interobserver variability (IOV). The aim of this study was (1) to develop an automated GTV delineation approach of primary tumor (GTVp) and pathologic lymph nodes (GTVn) based on a 3D convolutional neural network (CNN) exploiting multi-modality imaging input as required in clinical practice, and (2) to validate its accuracy, efficiency and IOV compared to manual delineation in a clinical setting. Methods Two datasets were retrospectively collected from 150 clinical cases. CNNs were trained for GTV delineation with consensus delineation as ground truth, with either single (CT) or co-registered multi-modal (CT + PET or CT + MRI) imaging data as input. For validation, GTVs were delineated on 20 new cases by two observers, once manually, once by correcting the delineations generated by the CNN. Results Both multi-modality CNNs performed better than the single-modality CNN and were selected for clinical validation. Mean Dice Similarity Coefficient (DSC)…

  36. 42
    top 5.5%

    First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer

    Michael J. Dubec, David L. Buckley, Michael Berks, Abigael Clough, John Gaffney and 15 more

    34 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109592OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Tumour hypoxia is prognostic in head and neck cancer (HNC), associated with poor loco-regional control, poor survival and treatment resistance. The advent of hybrid MRI - radiotherapy linear accelerator or 'MR Linac' systems - could permit imaging for treatment adaptation based on hypoxic status. We sought to develop oxygen-enhanced MRI (OE-MRI) in HNC and translate the technique onto an MR Linac system. MATERIALS AND METHODS: ) between air and oxygen gas breathing phases. We compared results from 1.5 T diagnostic MR and MR Linac systems. RESULTS: magnitude and time-course trends were similar on both systems. CONCLUSION: We demonstrate first-in-human translation of volumetric, dynamic OE-MRI onto an MR Linac system, yielding repeatable hypoxia biomarkers. Data were equivalent on the diagnostic MR and MR Linac systems. OE-MRI has potential to guide future clinical trials of biology guided adaptive radiotherapy.

  37. 43
    top 5.6%

    Treatment of oropharyngeal squamous cell carcinoma: Is swallowing quality better after TORS or RT?

    Flaminia Campo, Oreste Iocca, Armando DE VIRGILIO, Francesco Mazzola, Giuseppe Mercante and 5 more

    34 citationsdoi:10.1016/j.radonc.2023.109547OpenAlex

  38. 44
    top 5.7%

    Evaluation of therapeutic radiographer contouring for magnetic resonance image guided online adaptive prostate radiotherapy

    Gillian Adair Smith, Alex Dunlop, Sophie E. Alexander, Helen Barnes, Francis Casey and 17 more

    34 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2022.109457OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: The implementation of MRI-guided online adaptive radiotherapy has facilitated the extension of therapeutic radiographers' roles to include contouring, thus releasing the clinician from attending daily treatment. Following undergoing a specifically designed training programme, an online interobserver variability study was performed. MATERIALS AND METHODS: 117 images from six patients treated on a MR Linac were contoured online by either radiographer or clinician and the same images contoured offline by the alternate profession. Dice similarity coefficient (DSC), mean distance to agreement (MDA), Hausdorff distance (HD) and volume metrics were used to analyse contours. Additionally, the online radiographer contours and optimised plans (n = 59) were analysed using the offline clinician defined contours. After clinical implementation of radiographer contouring, target volume comparison and dose analysis was performed on 20 contours from five patients. RESULTS: Comparison of the radiographers' and clinicians' contours resulted in a median (range) DSC of 0.92 (0.86…

  39. 45
    top 5.8%

    Deep learning MRI-only synthetic-CT generation for pelvis, brain and head and neck cancers

    David Bird, Richard J. Speight, Sebastian Andersson, Jenny Wingqvist, Bashar M. Al‐Qaisieh

    33 citationsdoi:10.1016/j.radonc.2023.110052OpenAlex

  40. 46
    top 6%

    Radiomic feature repeatability and its impact on prognostic model generalizability: A multi-institutional study on nasopharyngeal carcinoma patients

    Jiang Zhang, Saikit Lam, Xinzhi Teng, Zongrui Ma, Xinyang Han and 10 more

    33 citationsOpen access (CC-BY-NC-ND)doi:10.1016/j.radonc.2023.109578OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: To investigate the radiomic feature (RF) repeatability via perturbation and its impact on cross-institutional prognostic model generalizability in Nasopharyngeal Carcinoma (NPC) patients. MATERIALS AND METHODS: 286 and 183 NPC patients from two institutions were included for model training and validation. Perturbations with random translations and rotations were applied to contrast-enhanced T1-weighted (CET1-w) MR images. RFs were extracted from primary tumor volume under a wide range of image filtering and discretization settings. RF repeatability was assessed by intraclass correlation coefficient (ICC), which was used to equally separate the RFs into low- and high-repeatable groups by the median value. After feature selection, multivariate Cox regression and Kaplan-Meier analysis were independently employed to develop and analyze prognostic models. Concordance index (C-index) and P-value from log-rank test were used to assess model performance. RESULTS: Most textural RFs from high-pass wavelet-filtered images were susceptible to image perturbations. It was…

  41. 47
    top 6.1%

    Evaluation of real-time tumor contour prediction using LSTM networks for MR-guided radiotherapy

    Elia Lombardo, Moritz Rabe, Yuqing Xiong, Lukas Nierer, Davide Cusumano and 9 more

    33 citationsdoi:10.1016/j.radonc.2023.109555OpenAlex

  42. 48
    top 6.2%

    Circulating tumour HPV16 DNA quantification – A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy

    Gabriel Adrian, Ola Forslund, Louise Pedersen, Johanna Sjövall, Maria Gebre‐Medhin

    32 citationsOpen access (CC-BY)doi:10.1016/j.radonc.2023.109773OpenAlex

    Show abstract

    BACKGROUND AND PURPOSE: Circulating tumour (ct) human papillomavirus (HPV) DNA is detectable in HPV-related oropharyngeal carcinoma (OPSCC) patients and has the potential to become an important clinical tool. This study aimed to evaluate the prognostic significance of ctHPV16-DNA kinetics during treatment with chemoradiotherapy in HPV-related OPSCC. Patients with p16-positive OPSCC recruited to the ARTSCAN III trial, comparing radiotherapy plus cisplatin with radiotherapy plus cetuximab, constituted the study cohort. MATERIALS AND METHODS: Blood samples before start and at the end of treatment of 136 patients were analysed. ctHPV16-DNA was quantified by real-time (q)PCR. The correlation between ctHPV16-DNA levels and tumour burden was investigated with Pearson regression analysis. The prognostic value of ctHPV16-DNA levels at baseline and decline during treatment was evaluated by area-under-the-curve (AUC) calculations and analysed with univariable and multivariable Cox proportional hazards models. RESULTS: ctHPV16-DNA was detectable with qPCR in 108/136 patients before start of…

  43. 49
    top 6.4%

    ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer

    Nina-Sophie Schmidt-Hegemann, Constantinos Zamboglou, Malcolm David Mason, Nicolas Mottet, Karel A. Hinnen and 8 more

    32 citationsOpen access (OTHER-OA)doi:10.1016/j.radonc.2023.109544OpenAlex

  44. 50
    top 6.5%

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to Radiotherapy and Oncology with publication year 2023, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 29 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.